GlassScriptPhysician profile
Mohammed Irshad
NPI 1508854589
$18,341.60
in general payments reported to CMS, 2019-2025
24 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,403 · 2020: $123 · 2021: $986 · 2022: $577 · 2023: $777 · 2024: $931 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $12K · Food and Beverage: $2,496 · Travel and Lodging: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $12,438.82 |
| Food and Beverage | $2,496.41 |
| Travel and Lodging | $317.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $12,944.17 | 2025 | Zymfentra, Vegzelma |
| Abbvie INC. | $1,435.92 | 2019-2025 | |
| Boston Scientific Corporation | $660.80 | 2019-2023 | Spyglass |
| Janssen Biotech, INC. | $552.80 | 2019-2024 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $367.47 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $359.28 | 2019-2024 | Entyvio |
| Allergan, INC. | $315.47 | 2019 | |
| Janssen Scientific Affairs, LLC | $236.90 | 2019-2022 | |
| Gilead Sciences, INC. | $234.43 | 2019-2025 | Epclusa |
| Daiichi Sankyo INC. | $215.15 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.54 | 2019-2022 | |
| Genzyme Corporation | $149.68 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $115.62 | 2023 | Rebyota |
| Madrigal Pharmaceuticals | $115.57 | 2024 | Rezdiffra |
| Pfizer INC. | $91.47 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $89.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $80.34 | 2021 | |
| Braintree Laboratories, INC. | $46.98 | 2019 | |
| Medtronic, INC. | $36.27 | 2024 | Pillcam, Gi Genius |
| Aimmune Therapeutics, INC. | $22.47 | 2025 | Zenpep |
| Ardelyx, INC. | $20.16 | 2025 | Ibsrela |
| Ucb, INC. | $18.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.48 | 2025 | Dupixent |
| Olympus America INC. | $14.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Irshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.